How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aceclidine-brimonidine-combination-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aceclidine+Brimonidine combination ophthalmic solution — Competitive Intelligence Brief

Aceclidine+Brimonidine combination ophthalmic solution (Aceclidine+Brimonidine combination ophthalmic solution) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic agonist + alpha-2 adrenergic agonist combination. Area: Ophthalmology.

phase 3 Muscarinic agonist + alpha-2 adrenergic agonist combination Muscarinic acetylcholine receptors; alpha-2 adrenergic receptors Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Aceclidine+Brimonidine combination ophthalmic solution (Aceclidine+Brimonidine combination ophthalmic solution) — LENZ Therapeutics, Inc. This combination stimulates muscarinic receptors (via aceclidine) and alpha-2 adrenergic receptors (via brimonidine) to increase aqueous humor outflow and reduce intraocular pressure in the eye.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aceclidine+Brimonidine combination ophthalmic solution TARGET	Aceclidine+Brimonidine combination ophthalmic solution	LENZ Therapeutics, Inc	phase 3	Muscarinic agonist + alpha-2 adrenergic agonist combination	Muscarinic acetylcholine receptors; alpha-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic agonist + alpha-2 adrenergic agonist combination class)

LENZ Therapeutics, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aceclidine+Brimonidine combination ophthalmic solution — Competitive Intelligence Brief. https://druglandscape.com/ci/aceclidine-brimonidine-combination-ophthalmic-solution. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab